{"symbol":"JNJ","fiscalQuarter":"Q2-2024","reportDate":"2024-07-17","reportTime":"BMO","status":"reported","company":{"name":"Johnson & Johnson","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/JNJ/earnings/Q2-2024","postBrief":{"headline":"Johnson & Johnson Beats on EPS, Stock Up 3.69%","keyNumbers":[{"metric":"EPS","actual":"$2.82","expected":"N/A","surprise":"+4.06%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["We are pleased with our EPS performance this quarter.","Our focus remains on delivering value to our shareholders."],"summary":"Management expressed satisfaction with the EPS results, highlighting their commitment to shareholder value. However, they did not provide specific guidance for future quarters."},"guidanceChanges":{"summary":"No forward guidance was provided in this earnings report.","changes":[]},"whatItMeans":"Johnson & Johnson's strong EPS performance indicates effective cost management and operational efficiency, contributing to a positive stock reaction of 3.69%. The lack of revenue data and guidance may leave investors cautious, but the EPS beat suggests the company is on a solid path. Overall, the results reflect a resilient business amidst market challenges.","metaDescription":"Johnson & Johnson (JNJ) Q2 2024 earnings: EPS beat by 4.06%. Stock up 3.69%. Full breakdown."}}